BCRX
BIOCRYST PHARMACEUTICALS INC
Key Financials
Operating Income
$341.0M
↑ 13508.9%
Net Income
$263.9M
↑ 396.9%
Revenue
$25.2M
↓ 4.4%
Total Liabilities
$633.3M
↓ 34.5%
EPS (Diluted)
$1.21
↑ 381.4%
Total Assets
$514.2M
↑ 4.8%
Shareholders' Equity
$-119153000.00
↑ 75.0%
Cash & Equivalents
$89.7M
↓ 14.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| SCHEDULE 13G | 8/7/2026 | View on SEC |
| S-8 | 8/5/2026 | View on SEC |
| 10-Q | 8/5/2026 | View on SEC |
| 8-K | 8/5/2026 | View on SEC |
| 8-K/A | 8/4/2026 | View on SEC |
| 8-K | 6/29/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
| 4 | 6/15/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | BCRX |
| Company Name | BIOCRYST PHARMACEUTICALS INC |
| CIK | 882796 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 919-859-1302 |